GNRO.PA

Geneuro SA

GNRO.PA, France

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program. In addition, the company has a collaborative development agreement with The National Institute of Neurological Disorders and Strokes for the development of an antibody program to block the activity of pHERV-K Env; and FondaMental Foundation for the development of diagnostic and therapeutic options for patients with Post-COVID neuropsychiatric syndromes, as well as research collaboration agreement with Northwestern University to confirm evidence of the expression of human endogenous retrovirus W envelope protein (W-ENV or W-ENV) in long-haul COVID patients; and US National Institute of Health for developing new approaches against pHERV-K (K-ENV) protein as a target in the treatment of amyotrophic lateral sclerosis. GeNeuro SA was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

https://www.geneuro.com

Stock Price

€0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2023-12-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.05

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.06 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.12 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.00% of the total shares of Geneuro SA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2023-12-31)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(0.5)
Value
Overpriced(0.5)

Income Statement

(Last Updated 2023-12-31)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-12-31)

Cash

€ 0

Short Term Investments

€ 0

Receivables

€ 0

Inventories

€ 0

Total Current Assets

€ 0

Property Plant Equipment

€ 0

Total Assets

€ 0

Payables

€ 0

Short Term Debt

€ 0

Long Term Debt

€ 0

Total Liabilities

€ 0

Equity

€ 0

Trend

Cash Flow

(Last Updated 2023-12-31)

Net Income

€ 0

Depreciation

€ 0

Change In Working Capital

€ 0

Cash From Operations

€ 0

Capital Expenditures

€ 0

Cash From Investing

€ 0

Cash From Financing

€ 0

Net Change In Cash

€ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.